Comparison of total and neutralizing SARS-CoV-2 spike antibodies against omicron and other variants in paired samples after two or three doses of mRNA vaccine

Recognizing that anti-SARS-CoV-2 antibody levels wane over time following the 2-dose SARS-CoV-2 mRNA series, the FDA approved a booster dose for people greater than 12 years old. Limited data exist on whether a booster dose of the mRNA vaccine results in greater antibody protection than the primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Debes, Amanda K., Xiao, Shaoming, Egbert, Emily R., Caturegli, Patrizio, Sitaras, Ioannis, Pekosz, Andrew, Milstone, Aaron M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820679/
https://www.ncbi.nlm.nih.gov/pubmed/35132427
http://dx.doi.org/10.1101/2022.01.26.22269819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820679/
https://www.ncbi.nlm.nih.gov/pubmed/35132427
http://dx.doi.org/10.1101/2022.01.26.22269819

Ejemplares similares